Skip to content
Home
  • Our science
    • What is Mass Transfer drying?
    • History
    • 5 benefits for biologics
    • Targeting high-value vaccines
    • Novel administration routes
  • LaminarPace
    • What is LaminarPace?
    • Mass Transfer drying – a new unit of production
    • Quality by Design and continuous development
    • 3D modelling and Tech Transfer
  • Projects
    • Ziccum’s project portfolio
    • 3-step process
    • Meet the project team
  • News
    • Press Releases
    • Ziccum Updates
  • Investors
    • Business model
    • Portfolio overview
    • Financial reports
    • IR portal
    • Calendar
    • Annual general meetings
    • Rights Issue Q1 2024
    • Rights Issue Q4 2024
    • Corporate governance
    • Owners
    • IR contact
    • Certified advisor
    • Presentations
    • Sustainability
    • Subscribe
  • About us
    • Bankruptcy administrator
    • Management team
    • Contact us

IR portal

Home » Investors » IR portal

Contact

e-mail: info@ziccum.com

ZICCUM AB
Scheelevägen 22
223 63 LUND
Sweden

About us

Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and also are highly suitable for novel administration routes.

Subscribe

Receive company data continuously to your inbox

Copyright © 2025 ZiccumTheme by SiteOrigin